- Partnership with Intermountain Health aims to enhance cancer surgery outcomes using OCT and AI technology.
- The collaboration supports Perimeter's FDA approval process for AI-enabled OCT systems.
- Potential expansion into additional tissue types beyond breast surgery is on the horizon.
Perimeter Medical Imaging AI (TSXV: PINK, OTCQX: PYNKF) has announced a strategic partnership with Intermountain Health, the largest nonprofit health system in the Intermountain West, through a Development Support Agreement (DSA). This collaboration is set to explore the clinical, social, and economic benefits of using Perimeter's Optical Coherence Tomography (OCT) and artificial intelligence (AI) technology to reduce cancer reoperations, particularly for breast-conserving surgery (BCS) patients.
In the initial study, Intermountain Health will focus on a retrospective analysis of reoperation rates and the associated incremental healthcare costs for patients who underwent BCS at selected hospital sites. The resulting data aims to fortify Perimeter's FDA premarket approval (PMA) process for its next-generation, AI-enabled OCT system.
Adrian Mendes, CEO of Perimeter, expressed excitement about the partnership's potential impact on commercial and market access strategies, noting that Intermountain Health’s integrated healthcare system offers a unique capability to evaluate total cancer reoperation costs. Teresa Reading, MD, Medical Director of Breast Surgery at Intermountain Health, highlighted the promising innovation of Perimeter's technology in optimizing surgical oncology outcomes, with future plans to expand the use of OCT to other tissue types beyond breast surgery.
Perimeter's OCT technology, which includes the Perimeter B-Series OCT with ImgAssist AI, is designed to improve cancer surgery with high-resolution, real-time imaging tools. This partnership marks a significant step in broadening the application of cutting-edge imaging technologies across cancer treatment practices.
